Co-Diagnostics, Inc. (NASDAQ:CODX) has a beta value of 0 and has seen 576,874 shares traded in the last trading session. The company, currently valued at $413.45 Million, closed the last trade at $14 per share which meant it lost -$0.07 on the day or -0.5% during that session. The CODX stock price is -121.36% off its 52-week high price of $30.99 and 93.93% above the 52-week low of $0.85. If we look at the company’s 10-day average daily trading volume, we find that it stood at 1.03 Million shares traded. The 3-month trading volume is 3.89 Million shares.

The consensus among analysts is that Co-Diagnostics, Inc. (CODX) is a Buy stock at the moment, with a recommendation rating of 2. None of the analysts rate the stock as a Sell, while none rate it as Overweight. None out of 3 have rated it as a Hold, with 3 advising it as a Buy. None have rated the stock as Underweight. The expected earnings per share for the stock is $0.63.

Co-Diagnostics, Inc. (NASDAQ:CODX) trade information

Wall Street analysts have a consensus price target for the stock at $35.33, which means that the shares’ value could jump 152.36% from current levels. The projected low price target is $30 while the price target rests at a high of $43. In that case, then, we find that the current price level is +207.14% off the targeted high while a plunge would see the stock lose 114.29% from current levels.

Co-Diagnostics, Inc. (CODX) estimates and forecasts

Figures show that Co-Diagnostics, Inc. shares have underperformed across the wider relevant industry. The company’s shares have lost -3.98% over the past 6 months, with this year growth rate of -550%, compared to -2.3% for the industry. Other than that, the company has, however, increased its growth outlook for the 2020 fiscal year revenue. Growth estimates for the current quarter are 730% and 855.6% for the next quarter. Revenue growth from the last financial year stood is estimated to be +43555.8%.

3 analysts offering their estimates for the company have set an average revenue estimate of $32.79 Million for the current quarter. 3 have an estimated revenue figure of $35.48 Million for the next quarter concluding in December 01, 2020. Year-ago sales stood $41Million and $109Million respectively for this quarter and the next, and analysts expect sales will grow by 79875.6% for the current quarter and 32450.5% for the next.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -22.6% over the past 5 years. Earnings growth for 2020 is a modest +26.4%.

Co-Diagnostics, Inc. (NASDAQ:CODX)’s Major holders

Insiders own 24.21% of the company shares, while shares held by institutions stand at 9.17% with a share float percentage of 12.1%. Investors are also buoyed by the number of investors in a company, with Co-Diagnostics, Inc. having a total of 30 institutions that hold shares in the company. The top two institutional holders are Blackrock Inc. with over 1.8 Million shares worth more than $34.86 Million. As of June 29, 2020, Blackrock Inc. held 6.42% of shares outstanding.

The other major institutional holder is Vanguard Group, Inc. (The), with the holding of over 1.3 Million shares as of June 29, 2020. The firm’s total holdings are worth over $25.2 Million and represent 4.64% of shares outstanding.

Also the top two Mutual Funds that are holding company’s shares are Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. As of June 29, 2020, the former fund manager holds about 2.67% shares in the company for having 748843 shares of worth $14.49 Million while later fund manager owns 554.98 Thousand shares of worth $6.05 Million as of August 30, 2020, which makes it owner of about 1.98% of company’s outstanding stock.